A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinib resistance in ALK-rearranged lung cancer.
A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinib resistance in ALK-rearranged lung cancer.
复制标题
临床配对耐药模型阐明了新型双重挽救信号,该信号在 ALK 重排肺癌中赋予艾乐替尼耐药性。
DOI:
--
复制
发表时间:
2018
期刊:
影响因子:
--
通讯作者:
Yuic
中科院分区:
文献类型:
--
作者:
Takahiro Tsuji;Hiroaki Ozasa;Wataru Aoki;Shunsuke Aburaya;Tomoko Funazo;Koh Furugaki;Yasushi Yoshimura;Hitomi Ajimizu;Ryoko Okutani;Yuto Yasuda;Takashi Nomizo;Kiyoshi Uemasu;Koichi Hasegawa;Hironori Yoshida;Yoshitaka Yagi;Hiroki Nagai;Yuic